Research Output per year
In my role as a research assistant, I am focussed on aiding the work performed for both mouse modelling of the ALL disease and clinical trials involving CML and ALL.
The development of xenograft and transgenic mouse models with a focus of T-ALL, will allow for the following to be investigated; the mechanisms of drug resistance, the development of new target therapies against newly discovered mutations, and how combination therapeutics could be a beneficial treatment option. These results will inform clinical practice, ultimately impacting on therapy responses and the survival of adults and children with high-risk ALL.
The clinical trials currently in progress include those that focussed on assessing the efficacy of tyrosine kinase inhibitors (TKI) on CML patients, as well as the cessation of TKI once remission is achieved. Trials are also looking into the efficacy of newly discovered drugs against CML. Trials have also begun on ALL patients, whereby our researchers are able to determine the subgroup of ALL a particular patient is a part of, as well as following the disease progression and aiding doctors in advising their patient on treatment options. As part of these trials, I aid fellow researchers in processing blood or bone marrow samples, entering data, and ensuring the safe preservation of cells and cellular products, ready for future investigative use.
Bachelor of Science (Honours), University of Adelaide
High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy RegimenYeung, D. T., Greenwood, M., Rhen, J., Heatley, S. L., McClure, B., Eadie, L. N., Breen, J., Schutz, C. S., Trahair, T. N., Wei, A. H., Dalla-Pozza, L., Sutton, R., Bradstock, K. F., Osborn, M. P. & White, D. L., 13 Nov 2019, In : Blood. 134, Supplement_1, p. 3949-3949 1 p.
Research output: Contribution to journal › Article